logo

Pacira Biosciences, Inc. (PCRX)



Trade PCRX now with
  Date
  Headline
9/21/2022 8:08:57 AM Pacira BioSciences Announces Positive Topline Data From Phase 3 Study Of EXPAREL
9/21/2022 8:02:13 AM Wedbush Reiterates Pacira BioSciences, Inc. (PCRX) At Outperform With $94 Price Target
9/7/2022 7:42:50 AM Pacira BioSciences Announces Positive Topline Data From Phase 3 Study Of EXPAREL
7/14/2022 7:37:47 AM Pacira BioSciences Reports Q2 Preliminary Revenue Of $169.4 Mln
4/12/2022 6:07:20 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) FY23 Rev. Estimate To 949.0 M From 1000.8 M
4/12/2022 6:06:30 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q4 23 Rev. Estimate To 250.1 M From 266.5 M
4/12/2022 6:06:12 PM Wedbush Is Lowering Pacira Pharmaceuticals, Inc. (PCRX) Q3 23 Rev. Estimate To 242.7 M From 256.8 M
4/12/2022 6:05:57 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q2 23 Rev. Estimate To 233.1 M From 244.8 M
4/12/2022 6:05:42 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q1 23 Rev. Estimate To 223.2 M From 232.7 M
4/12/2022 6:05:09 PM Wedbush Is Lowering Pacira Pharmaceuticals, Inc. (PCRX) FY22 Rev. Estimate To 721.5 M From 753.9 M
4/12/2022 6:04:51 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q4 22 Rev. Estimate To 201.7 M From 209.1 M
4/12/2022 6:04:37 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q3 22 Rev. Estimate To 184.7 M From 196.0 M
4/12/2022 6:04:09 PM Wedbush Is Lowering Pacira Pharmaceuticals, Inc. (PCRX) Q2 22 Rev. Estimate To 177.6 M From 181.9 M
4/12/2022 6:03:49 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q1 22 Rev. Estimate To 157.5 M From 166.8 M
4/12/2022 6:03:15 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) FY23 Estimate To 4.59 From 5.19
4/12/2022 6:02:57 PM Wedbush Is Cutting Pacira Pharmaceuticals, Inc. (PCRX) Q4 23 Estimate To 1.21 From 1.41